...
首页> 外文期刊>Current pharmaceutical design >Journey to the Center of the Cell: Current Nanocarrier Design Strategies Targeting Biopharmaceuticals to the Cytoplasm and Nucleus
【24h】

Journey to the Center of the Cell: Current Nanocarrier Design Strategies Targeting Biopharmaceuticals to the Cytoplasm and Nucleus

机译:前往细胞中心的旅程:将生物药物靶向细胞质和细胞核的当前纳米载体设计策略

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

New biopharmaceutical molecules, potentially able to provide more personalized and effective treatments, are being identified through the advent of advanced synthetic biology strategies, sophisticated chemical synthesis approaches, and new analytical methods to assess biological potency. However, translation of many of these structures has been significantly limited due to the need for more efficient strategies to deliver macromolecular therapeutics to desirable intracellular sites of action. Engineered nanocarriers that encapsulate peptides, proteins, or nucleic acids are generally internalized into target cells via one of several endocytic pathways. These nanostructures, entrapped within endosomes, must navigate the intracellular milieu to orchestrate delivery to the intended destination, typically the cytoplasm or nucleus. For therapeutics active in the cytoplasm, endosomal escape continues to represent a limiting step to effective treatment, since a majority of nanocarriers trapped within endosomes are ultimately marked for enzymatic degradation in lysosomes. Therapeutics active in the nucleus have the added challenges of reaching and penetrating the nuclear envelope, and nuclear delivery remains a preeminent challenge preventing clinical translation of gene therapy applications. Herein, we review cutting-edge peptide-and polymer-based design strategies with the potential to enable significant improvements in biopharmaceutical efficacy through improved intracellular targeting. These strategies often mimic the activities of pathogens, which have developed innate and highly effective mechanisms to penetrate plasma membranes and enter the nucleus of host cells. Understanding these mechanisms has enabled advances in synthetic peptide and polymer design that may ultimately improve intracellular trafficking and bioavailability, leading to increased access to new classes of biotherapeutics.
机译:通过先进的合成生物学策略,复杂的化学合成方法和评估生物学潜能的新分析方法的出现,正在鉴定出潜在地能够提供更多个性化和有效治疗方法的新生物药物分子。然而,由于需要更有效的策略将大分子治疗剂递送至所需的细胞内作用位点,因此许多这些结构的翻译受到显着限制。封装肽,蛋白质或核酸的工程化纳米载体通常通过几种内吞途径之一内化到靶细胞中。包裹在内体中的这些纳米结构必须在细胞内环境中导航,以协调向预期目的地(通常是细胞质或细胞核)的递送。对于在细胞质中具有活性的治疗剂,内体逃逸继续代表着有效治疗的限制步骤,因为内体中捕获的大多数纳米载体最终都被标记为溶酶体中的酶促降解。活跃在细胞核中的治疗药物面临着到达并穿透核膜的挑战,而核传递仍然是阻止基因治疗应用临床翻译的一项主要挑战。本文中,我们回顾了基于肽和聚合物的前沿设计策略,并有望通过改善细胞内靶向来显着改善生物药物功效。这些策略通常模仿病原体的活动,病原体已经发展出固有的,高效的机制来穿透质膜并进入宿主细胞的核。对这些机制的了解使合成肽和聚合物设计取得了进展,可以最终改善细胞内运输和生物利用度,从而导致获得更多新型生物疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号